Perfil
Dr Colas studied molecular biology at the University of Lyon and At the end of 1993, he joined the laboratory of Roger Brent, at the Department of Molecular Biology of Massachusetts General Hospital (Harvard Medical School, Boston, USA), where he contributed to the development of the peptide aptamer technology.
Dr Colas was recruited by the INSERM and came back to Lyon in 1998 to join Dr Rudkin's lab.
He pursued his work on peptide aptamer technologies.
In 2002, Dr Colas took a leave from the INSERM to become Scientific Director of Aptanomics.
Antiguos cargos conocidos de Pierre Colas.
| Empresas | Cargo | Fin |
|---|---|---|
Aptanomics SA
 Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France | Director Técnico/Científico/I+D | 24/01/2008 |
Formación de Pierre Colas.
| École Normale Supérieure de Lyon | Doctorate Degree |
| Ecole Centrale Lyon | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Aptanomics SA
Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France | Health Technology |
- Bolsa de valores
- Insiders
- Pierre Colas
